IL31 and atopic eczema: In AR, allergen‐stimulated PBMCs produce IL‐31 and correlate to the severity of the disease and its symptomatic manifestations, thus suggesting that IL‐31 may increase inflammation in the nasal epithelium through the release of mediators (CCL17, CCL22, and CCL1), which recruit inflammatory cells, as seen in Atopic dermatitis [5].